Methods A comprehensive search was conducted in PubMed, Web of Science, and OpenAlex for literature published between December 1, 2022, and December 31, 2024. Studies were included if they explicitly ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

Background: Optimal first line therapy for patients with metastatic melanoma is an immunotherapy regimen containing an anti-PD1 antibody, regardless of tumour BRAF mutation status. Anti-PD1 antibodies ...

Background: NIVO + RELA fixed-dose combination (FDC), compared with NIVO alone, demonstrated a clinically meaningful benefit to progression-free survival (HR 0.79, 95% CI 0.66–0.95) and overall ...

Background: PV is characterized by red blood cell overproduction. Rusfertide is a subcutaneous (SC), self-injected, first-in-class peptide hepcidin mimetic that decreases erythrocytosis. VERIFY ...

Between February 2023 and July 2024, we enrolled 125 of 174 approached caregivers (71.8%). Participants assigned to the BMT-CARE App used the app for a median of 146.9 minutes (range, 0-384.8). At day ...

Patients with suspected stage III-IV EOC should be evaluated by a gynecologic oncologist, with cancer antigen 125, computed tomography of the abdomen and pelvis, and chest imaging included. All ...

The purpose of this guideline is to update the ASCO evidence-based recommendations on the use of sentinel lymph node biopsy (SLNB) in early-stage breast cancer. ASCO first published a practice ...

Exacerbating these concerns, trial-related nonmedical costs may disproportionately affect lower socioeconomic status populations. A 2017 analysis of 1,600 cancer clinical trial participants found that ...

Neuroendocrine neoplasms (NENs) include poorly differentiated neuroendocrine carcinomas, well-differentiated neuroendocrine tumors (NETs), and mixed neuroendocrine non-NENs. 1 The focus of this ...

Recruitment for LCS programs faces numerous challenges, including socioeconomic, cultural, logistical, and racial disparities. Current LCS guidelines often fail to address differences in sex, smoking ...

Despite several randomized controlled trials demonstrating the benefits of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), a significant treatment gap persists. This ...